AI-designed 'universal vaccine' passes first human clinical trial, could prevent future pandemics

An AI-designed 'universal vaccine' targeting multiple coronaviruses has passed its first human clinical trial, showing safety and triggering an immune response in 39 volunteers. Developed by researchers from the Universities of Cambridge and Southampton, the vaccine uses a computer-simulated 'super-antigen' to combat evolving viruses, including those not yet discovered. The needle-free micro-fluid jet delivery method aims to simplify mass administration.